Coxsackie Virus IgM

Coxsackieviruses are highly contagious, non-enveloped RNA viruses belonging to the Enterovirus genus. They are responsible for a wide spectrum of diseases, ranging from mild febrile illnesses to severe neurological and cardiac complications. 

Accurate diagnosis through testing, such as Coxsackievirus IgM antibody testing and PCR assays, aids in differentiating active infections from other viral or bacterial conditions with similar clinical presentations.

What is Coxsackievirus?

Coxsackieviruses, classified within the Enterovirus genus of the Picornaviridae family, are non-enveloped RNA viruses that can cause a wide range of diseases. They are divided into two groups based on pathogenicity: Group A and Group B.

Both groups of coxsackieviruses can cause nonspecific febrile illnesses and aseptic meningitis, and both are associated with central nervous system diseases. 

Group A Coxsackievirus

Group A coxsackieviruses primarily affect the skin and mucous membranes, leading to conditions such as hand-foot-and-mouth disease (HFMD), herpangina, and acute hemorrhagic conjunctivitis. 

Notably, coxsackievirus A16 (CVA16) is a major cause of HFMD, with outbreaks often occurring in children. 

While CVA16 typically causes mild symptoms, severe complications such as aseptic meningitis and myocarditis have been reported, especially when co-infection with other enteroviruses like enterovirus 71 (EV71) occurs.

Additionally, CVA16 has been linked to a rare condition called acute flaccid myelitis (AFM), which affects the spinal cord and causes muscle weakness. 

An emerging concern is coxsackievirus A6 (CVA6), which became a significant cause of HFMD during an outbreak in Finland in 2008. While CVA16 and EV71 were traditionally linked to HFMD, CVA6 was identified as a key pathogen, with cases presenting with typical HFMD symptoms as well as unusual complications like onychomadesis (nail shedding). 

Understanding the evolving nature of coxsackievirus infections is important in identifying them; CVA6 is now considered an important pathogen to monitor, particularly during HFMD outbreaks.

Group B Coxsackievirus

Group B coxsackieviruses, including serotypes CVB1-CVB6, tend to target deeper tissues such as the heart, pancreas, and liver, causing conditions like myocarditis, pericarditis, pleurodynia (Bornholm disease), and hepatitis. 

CVB infections are also associated with severe outcomes such as neonatal systemic disease and have been implicated in the development of insulin-dependent diabetes. Coxsackievirus Group B is a major cause of viral myocarditis, especially in neonates and younger children.

Group B viruses are also recognized as a cause of aseptic meningitis, but their primary impact is on the organs mentioned above.

‍

Coxsackie Virus Transmission Routes

Coxsackieviruses are primarily transmitted through the fecal-oral route, which means that the virus spreads via contact with contaminated surfaces or food. 

The virus can also spread through respiratory droplets, making it highly contagious, particularly in close-contact settings like daycare centers and hospitals.

Common Clinical Manifestations of Coxsackie Virus

Coxsackie virus manifestations may depend on the viral strain and the organs affected. 

Hand, Foot, and Mouth Disease (HFMD)

This is the most common manifestation of CVA infections, characterized by fever, painful sores in the mouth, and a rash on the hands and feet. This condition is typically caused by CVA16 and EV-A71.

Herpangina

This infection, caused by CVA, leads to painful sores in the back of the throat, often seen in young children. It can be caused by Coxsackie viruses and Enterovirus 71.

Acute Hemorrhagic Conjunctivitis

This eye infection, caused by both CVA and CVB, results in redness, swelling, and bleeding in the conjunctiva.

Myocarditis and Pericarditis

CVB infections can cause inflammation of the heart muscle or the sac surrounding the heart. These conditions can be severe, particularly in young adults.

Pleurodynia (Bornholm Disease)

CVB is the primary cause of pleurodynia, which involves sudden sharp chest pain that may mimic a heart attack.

Meningitis

Both CVA and CVB can lead to inflammation of the membranes surrounding the brain and spinal cord, which can manifest as fever, headache, and neck stiffness.

What are Coxsackie IgM Antibodies?

IgM antibodies are antibodies produced by the immune system in response to a Coxsackie viral infection.

IgM antibodies against Coxsackie virus are typically produced during the early stages of infection. They indicate an active or recent infection with Coxsackie virus, as they are the first antibodies to appear in the immune response and activate the complement system to fight the viral infection. 

Elevated IgM levels, especially in the context of clinical symptoms such as herpetic-like outbreaks around the mouth, hands or feet, or other Coxsackie virus manifestations, can help confirm an active infection.

Who Should Get Tested for Coxsackievirus IgM Antibodies?

Coxsackievirus testing is primarily indicated for patients presenting with characteristic symptoms that suggest infection. 

These include oral sores combined with a rash (HFMD), painful throat lesions (herpangina), eye redness and swelling (acute hemorrhagic conjunctivitis), chest pain (pleurodynia), or symptoms of meningitis (fever, headache, and stiff neck). 

Testing is also critical in outbreak scenarios to confirm diagnoses and prevent viral spread.

Test Procedure and Interpretation

The following section outlines testing procedures and results interpretation for Coxsackie IgM Antibodies:

Test Procedure and Preparation Requirements

Coxsackie virus IgM Antibody testing typically requires a blood sample. A blood sample is generally collected via venipuncture. 

There are generally no specific preparation requirements for the patient, although it’s always important to confirm this with the ordering provider.

Normal Reference Ranges

Normal reference ranges for Coxsackie IgM Antibodies may vary slightly depending on the laboratory performing the test. However, a negative result generally indicates no detectable presence or immune response to Coxsackie virus at the time of testing. 

Clinical Implications of Elevated Levels

Elevated Coxsackie virus IgM Antibodies typically indicate that the patient is currently experiencing an active infection. Positive antibody responses must be interpreted within the context of the individual's presentation and medical history.

It is important to know that certain manifestations of the Coxsackie virus, particularly Hand, Foot, and Mouth disease, are diagnosed clinically and do not require serology testing. 

What Does a Negative Coxsackievirus Test Mean?

A negative Coxsackievirus test means that the virus is not detected, but this does not necessarily exclude the infection, as the viral load may be too low for detection or may not be present in the tested sample. 

It's also important to consider other possible diagnoses. A negative result does not rule out other infections or conditions with similar clinical presentations, such as bacterial infections or other viral illnesses like enteroviruses or herpes.

Order Coxsackie IgM Antibodies

Click here to compare testing options and order tests for Coxsackie antibodies.